Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$5.88 USD
+0.26 (4.63%)
Updated Jul 31, 2024 04:00 PM ET
After-Market: $5.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
AUPH 5.88 +0.26(4.63%)
Will AUPH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AUPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AUPH
Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
AUPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
Other News for AUPH
Aurinia Pharma Q2 2024 Earnings Preview
Notable earnings before Thursday's open
Noteworthy Monday Option Activity: AUPH, BYON, WCC
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
Aurinia Pharmaceuticals Announces Q2 Results Date